Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy

Heart failure (HF) is a leading cause of disease and death from cardiovascular diseases, with cardiovascular diseases accounting for the highest cases of deaths worldwide. The reality is that the quality-of-life survival for those suffering HF remains poor with 45–60% reported deaths within five yea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amy Hyein Kim, Jung Eun Jang, Jin Han
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Heart failure Heart failure with reserved ejection fraction (HFrEF) Heart failure with preserved ejection fraction (HFpEF) Diabetes Diabetic cardiomyopathy Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/6c96c6a6dfa849b295491abd86c3735f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c96c6a6dfa849b295491abd86c3735f
record_format	dspace
spelling	oai:doaj.org-article:6c96c6a6dfa849b295491abd86c3735f2021-11-28T04:28:25ZCurrent status on the therapeutic strategies for heart failure and diabetic cardiomyopathy0753-332210.1016/j.biopha.2021.112463https://doaj.org/article/6c96c6a6dfa849b295491abd86c3735f2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S075333222101249Xhttps://doaj.org/toc/0753-3322Heart failure (HF) is a leading cause of disease and death from cardiovascular diseases, with cardiovascular diseases accounting for the highest cases of deaths worldwide. The reality is that the quality-of-life survival for those suffering HF remains poor with 45–60% reported deaths within five years. Furthermore, cardiovascular disease is the foremost cause of mortality and disability in people with type 2 diabetes mellitus (T2DM), with T2DM patients having a two-fold greater risk of developing heart failure. The number of T2DM affected persons only continues to surge as there are more than 400 million adults affected by diabetes and an estimated 64.3 million affected by heart failure globally (1). In order to cater to the demands of modern society, the medical field has continuously improved upon the standards for clinical management and its therapeutic approaches. For this purpose, in this review, we aim to provide an overview of the current updates regarding heart failure, to include both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) and their respective treatments, while also diving further into heart failure and its correlation with diabetes and diabetic cardiomyopathy and their respective therapeutic approaches.Amy Hyein KimJung Eun JangJin HanElsevierarticleHeart failureHeart failure with reserved ejection fraction (HFrEF)Heart failure with preserved ejection fraction (HFpEF)DiabetesDiabetic cardiomyopathyTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 145, Iss , Pp 112463- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Heart failure Heart failure with reserved ejection fraction (HFrEF) Heart failure with preserved ejection fraction (HFpEF) Diabetes Diabetic cardiomyopathy Therapeutics. Pharmacology RM1-950
spellingShingle	Heart failure Heart failure with reserved ejection fraction (HFrEF) Heart failure with preserved ejection fraction (HFpEF) Diabetes Diabetic cardiomyopathy Therapeutics. Pharmacology RM1-950 Amy Hyein Kim Jung Eun Jang Jin Han Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
description	Heart failure (HF) is a leading cause of disease and death from cardiovascular diseases, with cardiovascular diseases accounting for the highest cases of deaths worldwide. The reality is that the quality-of-life survival for those suffering HF remains poor with 45–60% reported deaths within five years. Furthermore, cardiovascular disease is the foremost cause of mortality and disability in people with type 2 diabetes mellitus (T2DM), with T2DM patients having a two-fold greater risk of developing heart failure. The number of T2DM affected persons only continues to surge as there are more than 400 million adults affected by diabetes and an estimated 64.3 million affected by heart failure globally (1). In order to cater to the demands of modern society, the medical field has continuously improved upon the standards for clinical management and its therapeutic approaches. For this purpose, in this review, we aim to provide an overview of the current updates regarding heart failure, to include both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) and their respective treatments, while also diving further into heart failure and its correlation with diabetes and diabetic cardiomyopathy and their respective therapeutic approaches.
format	article
author	Amy Hyein Kim Jung Eun Jang Jin Han
author_facet	Amy Hyein Kim Jung Eun Jang Jin Han
author_sort	Amy Hyein Kim
title	Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
title_short	Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
title_full	Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
title_fullStr	Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
title_full_unstemmed	Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
title_sort	current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/6c96c6a6dfa849b295491abd86c3735f
work_keys_str_mv	AT amyhyeinkim currentstatusonthetherapeuticstrategiesforheartfailureanddiabeticcardiomyopathy AT jungeunjang currentstatusonthetherapeuticstrategiesforheartfailureanddiabeticcardiomyopathy AT jinhan currentstatusonthetherapeuticstrategiesforheartfailureanddiabeticcardiomyopathy
_version_	1718408383829114880

Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy

Ejemplares similares